Overall survival of chronic lymphocytic leukemia patients diagnosed over a 40-year period at a single institution (Catanzaro series). Patients are stratified according to age at the time of diagnosis.

Patients with CLL have several frontline treatment options ... acalabrutinib-venetoclax was associated with a significant improvement in overall survival (HR, 0.33; 95% CI, 0.18-0.56).

First CAR-T Approved for CLL In March, the FDA granted accelerated ... who historically have a poor expected overall survival [OS]," the researchers pointed out. For example, the study population ...

in patients with previously untreated CLL. Progression-free survival (PFS): time during and after treatment that a patient lives without the cancer getting worse. Overall survival (OS): time that a ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

"We're very encouraged by the efficacy we're seeing in these interim results and by the potential impact for CLL patients ... higher rate of progression-free survival (PFS) in patients treated ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia ... progression-free survival (PFS) reached 14 ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that ... improvement in progression-free survival (PFS), as well as a trend ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Overall survival (OS): time a patient lives after a diagnosis ... a clinically meaningful way to sustain BTK inhibition,” Sharman concluded. “BRUIN CLL-321: Randomized phase III trial of Jaypirca ...

Opens in a new tab or window SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously ...